PARP inhibitors show promise for treating ALS and other brain disorders

AstraZeneca’s Lynparza and Tesaro’s Zejula—part of an emerging class of cancer medicines known as PARP inhibitors—are on the market and being used to treat ovarian cancer with BRCA mutations. Now new research out of the University of Pennsylvania suggests this class of medicine could prove useful in treating some brain diseases, too.